AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-09-23. Numbers and descriptions here follow the published literature rather than marketing material.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Effective on new passenger cars sold in the United States after January 1, 1964. front outboard lap belts were required. On September 9, 1966, the National Traffic and Motor Vehicle Safety Act became law in the U.S., the first mandatory federal safety standards for motor vehicles. Effective in 1966, US-market passenger cars were required to be equipped with padded instrument panels, front and rear outboard lap belts, and white reverse (backup) lamps. In 1966, the U.S. established the United States Department of Transportation (DOT) with automobile safety as one of its purposes. The National Transportation Safety Board (NTSB) was created as an independent organization on April 1, 1967, but was reliant on the DOT for administration and funding. However, in 1975 the organization was made completely independent by the Independent Safety Board Act (in P.L. 93-633; 49 U.S.C. 1901). In 1967, equipment specifications by such major fleet purchasers as the City and County of Los Angeles, California, encouraged the voluntary installation in most new cars sold in the US of safety devices, systems, and design features including:
Different amino-acid sequences have different propensities for forming α-helical structure. Alanine, uncharged glutamate, leucine, charged arginine, methionine and charged lysine have especially high helix-forming propensities, whereas proline and glycine have poor helix-forming propensities. Proline either breaks or kinks a helix, both because it cannot donate an amide hydrogen bond (because it has none) and because its sidechain interferes sterically with the backbone of the preceding turn – inside a helix, which forces a bend of about 30° in the helix's axis. However, proline is often the first residue of a helix, presumably due to its structural rigidity. At the other extreme, glycine also tends to disrupt helices because its high conformational flexibility makes it entropically expensive to adopt the relatively constrained α-helical structure.
Chemical antagonism occurs when a chemical antagonist combines with a ligand to form an inactive product compound, inhibiting the response. In chemical antagonism, the receptors are not involved in the process, and the antagonist directly binds with or removes the ligand. It prevents the ligand from binding to the receptor. As the ligand cannot stimulate the receptor, no physiological effect is generated by the receptors and thus provides an inhibitory effect. The common types of chemical antagonism include chelating agents, neutralising antibodies and salt aggregation.
Trials to assess the effectiveness of an immunity passport scheme, also known as a COVID passport or COVID certification scheme, were confirmed by the UK government on 3 April 2021 as a way of helping to restart public events in England during the COVID-19 pandemic. The announcement was made following much discussion and speculation about the idea by politicians and in the British media. The government announced that trials of a scheme for England would begin on 16 April, starting with a comedy evening in Liverpool. In December 2021, COVID passports or similar verification methods became mandatory to access certain high-density venues per government regulations to address the spread of the infections Omicron variant of COVID-19.
Sources: en.wikipedia.org
The earliest known regulators of gene expression were proteins known as repressors and activators – regulators with specific short binding sites within enhancer regions near the genes to be regulated. Later studies have shown that RNAs also regulate genes. There are several kinds of RNA-dependent processes in eukaryotes regulating the expression of genes at various points, such as RNA interference repressing genes post-transcriptionally, long non-coding RNAs shutting down blocks of chromatin epigenetically, and enhancer RNAs inducing increased gene expression. Bacteria and archaea have also been shown to use regulatory RNA systems such as bacterial small RNAs and CRISPR. Fire and Mello were awarded the 2006 Nobel Prize in Physiology or Medicine for discovering microRNAs (miRNAs), specific short RNA molecules that can base-pair with mRNAs.
Serum, suspected to contain IgE antibodies, is drawn from the allergic (atopic) patient. This serum is injected intradermally into a non-allergic person. The suspected antigens are then intradermally injected into the non-allergic person 24–48 hours later. If the person being tested for an allergy has made antibodies for the antigen, this will cause a local reaction in the non-allergic person when the antibodies mix with the antigen. This demonstrates a type I hypersensitivity reaction, and the allergic reaction to the injected antigen is confirmed for the patient being tested. A positive PK test usually appears as a wheal and flare. The test was developed by Otto Prausnitz and Heinz Küstner. The first PK test occurred in 1921 when Prausnitz injected Küstner's serum into his abdominal skin. Küstner had previously noted that he developed allergic symptoms after eating fish. After eating some fish, Prausnitz's skin became hot, red, and swollen at the site of the serum injection, confirming their hypothesis that Küstner was allergic to fish.
The Department works at the intersection of organic chemistry (chemistry of natural products, chemistry of macrocyclic compounds, chemistry of elementorganic compounds), supramolecular chemistry (solution and self-process chemistry) and molecular biology. The head of the Department is Professor Igor S. Antipin, a corresponding member of the Russian Academy of Science, Doctor of Chemistry. The Department conducts research in the following fields:
Amino acids are the building blocks of protein and together they form the protein requirements in formula needed for growth and development. The amino acids are in the simplest form, making it easy for the body to process and digest. Amino acid-based formula may be considered hypoallergenic since it does not contain peptides that may trigger an immune response. Because infants and children have different nutritional needs, amino acid-based formulas are typically formulated either for infants 0–1 years of age or for children 1–10 years of age. Amino acid-based formulas may be used for those with cow's milk or soy protein allergy. However, most infants who suffer from food allergy respond well to extensively hydrolysed formulas, and only few of those with the most severe form of the illness require the use of amino acid-based formulas. It may also be used for other medical conditions requiring an amino acid-based diet, such as short bowel syndrome, and for transition from parenteral to enteral nutrition. Milk allergy Food allergy
AlphaFold 2 scoring more than 90 in CASP's global distance test (GDT) was considered a great achievement in computational biology. Nobel Prize winner and structural biologist Venki Ramakrishnan called the result "a stunning advance on the protein folding problem", adding that "It has occurred decades before many people in the field would have predicted. It will be exciting to see the many ways in which it will fundamentally change biological research." AlphaFold 2's success received wide media attention. News pieces appeared in the science press, such as Nature, Science, MIT Technology Review, and New Scientist, and the story was covered by national newspapers. A frequent theme was the ability to predict protein structures based on the constituent amino acid sequence, expected to have benefits in the life sciences—accelerating drug discovery and enabling better understanding of diseases. Some have noted that even a perfect answer to the protein prediction problem still leaves questions about the protein folding problem (and thus protein dynamics)—understanding in detail how the folding process actually occurs in nature (and how sometimes they can also misfold).
Sources: en.wikipedia.org
The AToFMS allows for the determination of mixing state, or distribution of chemical species, within individual particles. These mixing states are important in the determination of climate and health impact of aerosols. The schematic of a typical AToFMS is shown to the right. The overall structure of ATOF instruments is; sampling, sizing, and the mass analyzer region. The inlet system is similar to the AMS by using the same aerodynamic focusing lens, but it has smaller orifices because of its analysis of single particles. In the sizing region particle passes through the first continuous solid state laser that generates an initial pulse of scattered light. Then the particle passes through the second laser that is orthogonal to the first and produces a pulse of scattered light. The light is detected by a photomultiplier (PMT) that is matched up to each laser. Using the transit times between the two detected pulses and the fixed distance the velocity and size of each particle is calculated. Next the particles travel through to the mass analyzer region where it is ionized by a pulsed LDI laser, which is timed to hit the particle as it reaches the center of the ion extraction region. Once ionized, the positive ions are accelerated towards the positive ToF section and the negative ions are accelerated towards the negative ToF section where they are detected.
Integrator complex subunit 15, also known as C7orf26, is a protein encoded in humans by the INTS15 gene. Based on properties of c7orf26 and its conservation over a long period of time, its suggested function is targeted for the cytoplasm and it is predicted to play a role in regulating transcription. Chromosome 7 is one of the 23 pairs of chromosomes in the human body, and spans about 159 million base pairs and represents about 5-5.5% of the total DNA in cells. Changes to the structure of chromosome 7 can result in a number of genetic abnormalities, including Williams Syndrome which causes structural and cosmetic changes to the human body, ultimately resulting in a shorter lifespan. There are hundreds of known open reading frames (ORF) along the domain of chromosome 7, however there is not much known about the 26th reading frame, which is of considerable interest. Currently, two isoforms of c7orf26 are known in Homo Sapiens and are referred to as isoforms 1 and 2, respectively.
Inositol nicotinate, also known as inositol hexanicotinate or inositol hexaniacinate, is a compound of niacin (vitamin B3) and inositol. It is marketed in the United States as a "no-flush" form of niacin in dietary supplements. When ingested, inositol nicotinate breaks down into inositol and niacin. The niacin component helps widen blood vessels (vasodilation), lowers blood lipid levels (including cholesterol), and inhibits a protein involved in blood clotting. Inositol nicotinate is used to treat blood circulation problems, including: Raynaud's phenomenon Intermittent claudication Some research shows it can improve symptoms of Raynaud's phenomenon over several weeks. However, its effectiveness in treating other conditions like: High cholesterol High blood pressure Leg pain during exercise (due to poor circulation) remains unclear, with studies producing mixed results. Other proposed uses, such as for: Migraines Psoriasis Restless legs syndrome have insufficient supporting evidence. Inositol nicotinate is generally safe when taken by mouth, but possible side effects include:
The tree was created by maximum likelihood analysis without bootstrap: consequently accuracy is traded off for size and many phylum level clades are not correctly resolved (such as the Firmicutes). (Eukaryotes not present in analysis). This phylogeny is a summary of the 16S rRNA based LTP_07_2026 and contains all type species with validly published names up to July 2026. Branching order of bacterial phyla (Woese, 1987) Branching order of bacterial phyla (Gupta, 2001) Branching order of bacterial phyla (Cavalier-Smith, 2002) Branching order of bacterial phyla (Rappe and Giovanoni, 2003) Branching order of bacterial phyla (Battistuzzi et al., 2004) Branching order of bacterial phyla (Ciccarelli et al., 2006) Branching order of bacterial phyla (Genome Taxonomy Database, 2018) Bacterial phyla List of Archaea genera List of bacteria genera List of bacterial orders LPSN, list of accepted bacterial and archaeal names http://www.arb-silva.de/projects/living-tree/
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.